Earnings

C4 Therapeutics Q2 EPS $(0.18) Beats $(0.23) Estimate, Sales $6.641M Beat $4.000M Estimate

Aug 11, 2026 · 07:34 AM ET· updated 2h ago

C4 Therapeutics (NASDAQ:CCCC) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.23) by 21.74 percent. This is a 51.35 percent increase over losses of $(0.37) per share from

Why It Matters

C4 Therapeutics lost less money than experts thought it would, and made more sales than expected. When a company doing research loses less money and grows sales faster, it shows the business is getting stronger.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

CCCC3.75

+0.13 (+3.45%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.